The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of . NurOwn has been administered to over 30 patients with amyotrophic lateral sclerosis in clinical trials conducted in Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements.
http://ift.tt/1mVfOTG
http://ift.tt/1mVfOTG
No comments:
Post a Comment